Puma Biotechnology Operating Income Over Time
| PBYI Stock | USD 6.94 0.15 2.21% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Puma Biotechnology Performance and Puma Biotechnology Correlation. Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Puma Biotechnology and related stocks such as Eledon Pharmaceuticals, Abeona Therapeutics, and Voyager Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELDN | (9.6 M) | (9.6 M) | (9.6 M) | (15.7 M) | (23.5 M) | (45.3 M) | (38.1 M) | (13.1 M) | (14.1 M) | (14.2 M) | (13.3 M) | (36.9 M) | (39.8 M) | (43 M) | (70.6 M) | (63.5 M) | (60.3 M) |
| ABEO | 341 K | (7.9 M) | (4.3 M) | (3.8 M) | (3.1 M) | (18.5 M) | (23.9 M) | (27.8 M) | (58.2 M) | (77.1 M) | (81.4 M) | (89.8 M) | (50.9 M) | (47.1 M) | (64.2 M) | (57.8 M) | (54.9 M) |
| VYGR | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (14.4 M) | (20.3 M) | (41.3 M) | (71.9 M) | (91.1 M) | (51.7 M) | 27.4 M | (73.6 M) | (50.8 M) | 122 M | (83.3 M) | (95.8 M) | (91 M) |
| AVIR | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (14.6 M) | (11 M) | 138.4 M | (130.7 M) | (164.2 M) | (192.9 M) | (173.7 M) | (165 M) |
| ARCT | (3.9 M) | (3.9 M) | (1.5 M) | (10.3 M) | (33.1 M) | (19.7 M) | (25.2 M) | (10.5 M) | (21.8 M) | (25.5 M) | (71.5 M) | (202.9 M) | 12.2 M | (78.2 M) | (95.7 M) | (86.1 M) | (81.8 M) |
| ALLO | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (192.8 M) | (202 M) | (258.2 M) | (255.8 M) | (335.4 M) | (327.7 M) | (273.2 M) | (245.9 M) | (258.2 M) |
| HUMA | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (64.6 M) | (81.2 M) | (84.6 M) | (100 M) | (114.4 M) | (103 M) | (108.1 M) |
| TRDA | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (26.7 M) | (51.1 M) | (97.2 M) | (3.2 M) | 47 M | 54.1 M | 56.8 M |
| SGMT | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (11.4 M) | (23.7 M) | (31.1 M) | (30.7 M) | (54.5 M) | (49 M) | (46.6 M) |
Puma Biotechnology and related stocks such as Eledon Pharmaceuticals, Abeona Therapeutics, and Voyager Therapeutics Operating Income description
Operating Income is the amount of profit realized from Puma Biotechnology operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Puma Biotechnology is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Puma Biotechnology | PBYI |
| Classification | Biotech |
| Business Address | 10880 Wilshire Boulevard, |
| Exchange | NASDAQ Exchange |
USD 6.94
Check out Puma Biotechnology Performance and Puma Biotechnology Correlation. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Puma Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.